Sydney Brain Bank
FACILITY INFORMATION
PROCESSES
Collection
The brain donation occurs as soon as possible after death. This is done with the utmost care and respect by highly trained staff who perform the brain removals. The limited autopsies are usually carried out at the nearest participating hospital that has appropriate mortuary facilities. After the procedure, the tissue is transported back to the Sydney Brain Bank where it is processed and held.
Brain tissue arrives at the Sydney Brain Bank and is processed and stored in different ways as a means of offering the greatest options for researchers who may want to utilise the tissues for their experiments. This may include freezing some of the tissue so that it can be used for DNA extraction and/or biochemical studies. This is done in the shortest time period possible to ensure viability of most neurochemicals, proteins and RNAs. For participants with a strong family history of disease, the DNA may be screened for genes in which rare mutations have already been associated with neurodegeneration. The remaining tissue is fixed in formalin to preserve it for histological examination.
Characterisation
All brains undergo thorough microscopic examination to characterise each case according to the latest published diagnostic criteria (see list below). This information is communicated to the donors’ recruiting brain donor program. All tissue samples are de-identified to ensure anonymity of the donor.
Examples of common neuropathology
Latest published neuropathologial diagnostic criteria
National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Hyman et al. Alzheimers Dement. 2012 Jan;8(1):1-13. A harmonized classification system for FTLD-TDP pathology. Mackenzie IR et al; Acta Neuropathol. 2011 Jul;122(1):111-3 Distinct pathological subtypes of FTLD-FUS. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeber S, Kretzschmar HA, Cairns NJ, Neumann M. Acta Neuropathol. 2011 Feb;121(2):207-18. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I; Office of Rare Diseases of the National Institutes of Health. J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. J Neuropathol Exp Neurol. 1996 Jan;55(1):97-105. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Ahmed Z, Doherty KM, Silveira-Moriyama L, Bandopadhyay R, Lashley T, Mamais A, Hondhamuni G, Wray S, Newcombe J, O’Sullivan SS, Wroe S, de Silva R, Holton JL, Lees AJ, Revesz T. Acta Neuropathol. 2011 Oct;122(4):415-28. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL 3rd, Wisniewski T, Woulfe JM, Yamada M, Dickson DW. Acta Neuropathol. 2016 Jan;131(1):87-102. The genetics and neuropathology of amyotrophic lateral sclerosis. Al-Chalabi A, et al; Acta Neuropathol. 2012 Sep;124(3):339-52. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Dickson DW et al; Lancet Neurol. 2009 Dec;8(12):1150-7. Review. Erratum in: Lancet Neurol. 2010 Feb;9(2):140. Lancet Neurol. 2010 Jan;9(1):29 Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG et al; Neurology. 2005 Dec 27;65(12):1863-72. Review. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M; Neurology. 2005 Dec 27;65(12):1863-72. Review. Erratum in: Neurology. 2005 Dec 27;65(12):1992 Second consensus statement on the diagnosis of multiple system atrophy. Gilman S et al; Neurology. 2008 Aug 26;71(9):670-6. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Jellinger KA et al; Mov Disord. 2005 Aug;20 Suppl 12:S29-36. Neuropathological classification of Huntington’s disease. Vonsattel et al 1985. JNEN. 44:559-577Alzheimer’s disease
Frontotemporal Lobar Degeneration (FTLD)-TDP
Frontotemporal Lobar Degeneration (FTLD)-FUS
Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy (PSP)
Globular Glial Tauopathy (GGT)
Aging-related tau astrogliopathy (
ARTAG)Motor Neuron Disease
Parkinson's Disease
Dementia with Lewy Bodies (DLB)
Multiple System Atrophy
Huntington’s disease
